Literature DB >> 23239501

Low sphingosine-1-phosphate impairs lung dendritic cells in cystic fibrosis.

Yaqin Xu1, Anja Krause, Maria Limberis, Tilla S Worgall, Stefan Worgall.   

Abstract

Dysfunction of the cystic fibrosis transmembrane regulator (CFTR) leads to chronic inflammation and infection of the respiratory tract. The role of CFTR for cells of the pulmonary immune system is only partly understood. The present study analyzes the phenotype and immune stimulatory capacity of lung dendritic cells (DCs) from CFTR knockout (CF) mice. Total numbers of conventional DCs, plasmacytoid DCs, and CD103-positive DCs were lower in CF mice compared with wild-type (WT) control mice, as was the expression of major histocompatibility complex class II molecules (MHCII), CD40, and CD86. After pulmonary infection with respiratory syncytial virus, DC numbers increased in WT mice but not in CF mice, and the T cell-stimulatory capacity of CF DCs was impaired. The culture of CF lung DCs with bronchoalveolar lavage fluid (BALF) from WT mice increased the expression of MHCII, CD40, and CD86. The supplementation of CF BALF with sphingosine-1-phosphate (S1P), a mediator of immune cell migration and activation that is decreased in CF BALF, rescued the reduced expression of MHCII and CD40 in WT lung DCs and human blood DCs. These findings suggest that DCs are impaired in the CF lung, and that altered S1P affects lung DC function. These findings provide a novel link between defective CFTR and pulmonary innate immune dysfunction in CF.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23239501      PMCID: PMC3604068          DOI: 10.1165/rcmb.2012-0021OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  55 in total

1.  CFTR may play a role in regulated secretion by lymphocytes: a new hypothesis for the pathophysiology of cystic fibrosis.

Authors:  J K Bubien
Journal:  Pflugers Arch       Date:  2001-07-07       Impact factor: 3.657

2.  The Sphingosine-1 Phosphate receptor agonist FTY720 dose dependently affected endothelial integrity in vitro and aggravated ventilator-induced lung injury in mice.

Authors:  Holger Christian Müller; Andreas Christian Hocke; Katharina Hellwig; Birgitt Gutbier; Harm Peters; Stefanie Maria Schönrock; Thomas Tschernig; Andreas Schmiedl; Stefan Hippenstiel; Philippe Dje N'Guessan; Simone Rosseau; Norbert Suttorp; Martin Witzenrath
Journal:  Pulm Pharmacol Ther       Date:  2011-03-23       Impact factor: 3.410

3.  Inflammatory lung secretions inhibit dendritic cell maturation and function via neutrophil elastase.

Authors:  Ali Roghanian; Ellen M Drost; William MacNee; Sarah E M Howie; Jean-Michel Sallenave
Journal:  Am J Respir Crit Care Med       Date:  2006-09-07       Impact factor: 21.405

4.  Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis.

Authors:  P W Hiatt; S C Grace; C A Kozinetz; S H Raboudi; D G Treece; L H Taber; P A Piedra
Journal:  Pediatrics       Date:  1999-03       Impact factor: 7.124

Review 5.  Murine models of acute and chronic lung infection with cystic fibrosis pathogens.

Authors:  Alessandra Bragonzi
Journal:  Int J Med Microbiol       Date:  2010-10-14       Impact factor: 3.473

6.  Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis.

Authors:  E E Wang; C G Prober; B Manson; M Corey; H Levison
Journal:  N Engl J Med       Date:  1984-12-27       Impact factor: 91.245

7.  RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells.

Authors:  Bart E Van Ewijk; Tom F W Wolfs; Piet C Aerts; Kok P M Van Kessel; Andre Fleer; Jan L L Kimpen; Cornelis K Van der Ent
Journal:  Pediatr Res       Date:  2007-04       Impact factor: 3.756

8.  Respiratory syncytial virus infection in a murine model of cystic fibrosis.

Authors:  Giuseppe N Colasurdo; Jason J Fullmer; Okan Elidemir; Constance Atkins; Amir M Khan; James M Stark
Journal:  J Med Virol       Date:  2006-05       Impact factor: 2.327

Review 9.  A novel approach to analyze gene expression data demonstrates that the DeltaF508 mutation in CFTR downregulates the antigen presentation pathway.

Authors:  Thomas H Hampton; Bruce A Stanton
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-12-31       Impact factor: 5.464

10.  In vitro T cell responses in patients with cystic fibrosis and allergic bronchopulmonary aspergillosis.

Authors:  A P Knutsen; R G Slavin
Journal:  J Lab Clin Med       Date:  1989-04
View more
  12 in total

Review 1.  Advancements in understanding the role of lysophospholipids and their receptors in lung disorders including bronchopulmonary dysplasia.

Authors:  Tara Sudhadevi; Alison W Ha; David L Ebenezer; Panfeng Fu; Vijay Putherickal; Viswanathan Natarajan; Anantha Harijith
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2020-03-10       Impact factor: 4.698

2.  Post-exposure immunization by capsid-modified AdC7 vector expressing Pseudomonas aeruginosa OprF clears P. aeruginosa respiratory infection.

Authors:  Rika Gomi; Anurag Sharma; Wenzhu Wu; Biin Sung; Stefan Worgall
Journal:  Vaccine       Date:  2017-11-07       Impact factor: 3.641

Review 3.  Bone disease in cystic fibrosis: new pathogenic insights opening novel therapies.

Authors:  J Jacquot; M Delion; S Gangloff; J Braux; F Velard
Journal:  Osteoporos Int       Date:  2015-10-02       Impact factor: 4.507

4.  Sphingosine-1-phosphate receptor 1 agonism attenuates lung ischemia-reperfusion injury.

Authors:  Matthew L Stone; Ashish K Sharma; Yunge Zhao; Eric J Charles; Mary E Huerter; William F Johnston; Irving L Kron; Kevin R Lynch; Victor E Laubach
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-04-24       Impact factor: 5.464

Review 5.  Targeting sphingosine-1-phosphate signaling in lung diseases.

Authors:  David L Ebenezer; Panfeng Fu; Viswanathan Natarajan
Journal:  Pharmacol Ther       Date:  2016-09-13       Impact factor: 12.310

Review 6.  Sphingosine 1-Phosphate: A Novel Target for Lung Disorders.

Authors:  Sabira Mohammed; K B Harikumar
Journal:  Front Immunol       Date:  2017-03-14       Impact factor: 7.561

7.  CFTR Knockdown induces proinflammatory changes in intestinal epithelial cells.

Authors:  Karoline St-Martin Crites; Geneviève Morin; Valérie Orlando; Natacha Patey; Catherine Cantin; Judith Martel; Emmanuelle Brochiero; Geneviève Mailhot
Journal:  J Inflamm (Lond)       Date:  2015-11-07       Impact factor: 4.981

8.  A Link Between a Common Mutation in CFTR and Impaired Innate and Adaptive Viral Defense.

Authors:  Emma Svedin; Renata Utorova; Michael H Hühn; Pär G Larsson; Virginia M Stone; Manasa Garimella; Katharina Lind; Thomas Hägglöf; Terezia Pincikova; Olli H Laitinen; Gerald M McInerney; Bob Scholte; Lena Hjelte; Mikael C I Karlsson; Malin Flodström-Tullberg
Journal:  J Infect Dis       Date:  2017-12-05       Impact factor: 5.226

9.  Plasma Levels of the Bioactive Sphingolipid Metabolite S1P in Adult Cystic Fibrosis Patients: Potential Target for Immunonutrition?

Authors:  Emina Halilbasic; Elisabeth Fuerst; Denise Heiden; Lukasz Japtok; Susanne C Diesner; Michael Trauner; Askin Kulu; Peter Jaksch; Konrad Hoetzenecker; Burkhard Kleuser; Lili Kazemi-Shirazi; Eva Untersmayr
Journal:  Nutrients       Date:  2020-03-14       Impact factor: 5.717

10.  Therapeutic CFTR Correction Normalizes Systemic and Lung-Specific S1P Level Alterations Associated with Heart Failure.

Authors:  Franziska E Uhl; Lotte Vanherle; Frank Matthes; Anja Meissner
Journal:  Int J Mol Sci       Date:  2022-01-14       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.